Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cidara Therapeutics Inc

CDTX
Current price
26.49 USD +1.5 USD (+6.00%)
Last closed 21.04 USD
ISIN US1717572069
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 272 884 608 USD
Yield for 12 month +135.26 %
1Y
3Y
5Y
10Y
15Y
CDTX
21.11.2021 - 28.11.2021

Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California. Address: 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

36.60 USD

P/E ratio

Dividend Yield

Current Year

+1 275 000 USD

Last Year

+63 905 000 USD

Current Quarter

Last Quarter

Current Year

+1 042 000 USD

Last Year

+62 382 000 USD

Current Quarter

Last Quarter

Key Figures CDTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -107 792 000 USD
Operating Margin TTM -35 743.71 %
Price to Earnings
Return On Assets TTM -55.20 %
PEG Ratio
Return On Equity TTM -299.58 %
Wall Street Target Price 36.60 USD
Revenue TTM 302 000 USD
Book Value 11.61 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100.00 %
Dividend Yield
Gross Profit TTM -71 800 000 USD
Earnings per share -26.68 USD
Diluted Eps TTM -26.68 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CDTX

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History CDTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 1:20
Payout Ratio TTM
Last Split Date 24.04.2024

Stock Valuation CDTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 5.75
Enterprise Value Revenue 358.45
Price Sales TTM 903.59
Enterprise Value EBITDA -1.64
Price Book MRQ 1.93

Financials CDTX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CDTX

For 52 weeks

10.14 USD 28.42 USD
50 Day MA 20.60 USD
Shares Short Prior Month 480 028
200 Day MA 17.63 USD
Short Ratio 2.80
Shares Short 452 539
Short Percent 3.61 %